TOWA PHARMACEUTICAL CO.,LTD. (4553.T) Financial Statements

Income statement

Metric	TTM	2026	2025	2024	2023
Revenue
Total Revenue	269.9B	273.7B	259.6B	227.9B	208.9B
Cost of Revenue	41.5B	174.6B	164.9B	146.6B	136.1B
Gross Profit	23.7B	99.1B	94.7B	81.4B	72.7B
Operating Expenses
R&D Expense	—	—	—	—	—
SG&A Expense	18.5B	76.0B	71.5B	63.7B	67.2B
General & Admin Expense	—	—	—	—	—
Selling & Marketing Expense	—	—	—	—	—
Other Expenses	—	—	—	—	—
Total Operating Expenses	18.5B	76.0B	71.5B	63.7B	67.2B
Cost and Expenses	245.8B	250.6B	236.4B	210.3B	203.3B
Operating Income (EBIT)	24.1B	23.1B	23.2B	17.6B	5.5B
Non-Operating
Interest Income	61.0M	309.0M	221.0M	97.0M	17.0M
Interest Expense	540.0M	2.3B	1.6B	947.0M	635.0M
Net Interest Income	(479.0M)	(2.0B)	(1.4B)	(850.0M)	(618.0M)
Other Non-Op Income/Expense	(1.3B)	5.0B	2.9B	6.8B	(373.0M)
Non-Operating Income (excl Interest)	708.0M	7.2B	4.7B	8.0B	2.9B
EBT (Pre-Tax Income)	4.0B	13.2B	26.3B	24.5B	4.6B
Income Tax Expense	1.4B	7.9B	7.3B	8.3B	2.4B
Bottom Line
Net Income	21.4B	5.3B	19.0B	16.2B	2.2B
Earnings from Cont. Ops	—	—	—	—	—
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	21.4B	5.3B	19.0B	16.2B	2.2B
Per Share
Basic EPS	¥436	¥107	¥386	¥329	¥45
Diluted EPS	¥436	¥107	—	—	—
Revenue Per Share	¥5,483	¥5,560	¥5,274	¥4,631	¥4,243
Shares
Basic Shares Outstanding	49.2M	49.2M	49.2M	49.2M	49.2M
Diluted Shares Outstanding	—	—	—	—	—
Profitability Metrics
EBITDA	9.3B	41.4B	38.9B	31.3B	19.8B
D&A	4.1B	18.3B	15.7B	13.7B	14.3B
EBIT	24.1B	23.1B	23.2B	17.6B	5.5B

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026